Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study
Michael B. Lilly(Medical University of South Carolina), Giovanni Martinelli(University of Bologna), Aude Charbonnier(Institut Paoli-Calmettes), Gerhard Ehninger(University Hospital Carl Gustav Carus), Eduardo Bullorsky(Hospital Británico de Buenos Aires), M. Brigid Bradley‐Garelik(Bristol-Myers Squibb (United States)), Oliver G. Ottmann(Cardiff University), Chao Zhu(Bristol-Myers Squibb (Germany)), Richard A. Larson(Urbana University), Martin C. Müller(Universität Hamburg), Hervé Dombret(University of London Institute in Paris), Josy Reiffers(Thrombolysis in Myocardial Infarction Study Group), Neil P. Shah(University of California, San Francisco)
Cited by 98
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k